Dendroaspis natriuretic peptide

Drug Profile

Dendroaspis natriuretic peptide

Latest Information Update: 10 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Class Amino acids
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 10 Dec 2007 Discontinued - Preclinical for Congestive heart failure in USA (unspecified route)
  • 24 Aug 2006 No development reported - Preclinical for Congestive heart failure in USA (unspecified route)
  • 19 Mar 2002 A study has been added to the Heart Failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top